{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:42:59Z","timestamp":1762605779475,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100031566","name":"Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.vhri.2024.101013","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:18:55Z","timestamp":1720444735000},"page":"101013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Health-Related Quality of Life in Chronic Pain Treated With Tapentadol Versus Oxycodone\/Naloxone and Its Determinants: A Real-World, Single-Center Retrospective Cohort Study in Spain"],"prefix":"10.1016","volume":"44","author":[{"given":"Ana M.","family":"Peir\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Grimby-Ekman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Barrachina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Escorial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"Margarit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Selva-Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ger\u00f3nimo-Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2024.101013_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.pnpbp.2019.04.006","article-title":"The silent epidemic of chronic pain in older adults","volume":"93","author":"Domenichiello","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.vhri.2024.101013_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur J Pain"},{"issue":"8","key":"10.1016\/j.vhri.2024.101013_bib4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.socscimed.2011.02.034","article-title":"Understanding how race\/ethnicity and gender define age-trajectories of disability: an intersectionality approach","volume":"72","author":"Warner","year":"2011","journal-title":"Soc Sci Med"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1213\/ANE.0000000000001683","article-title":"Trends in tramadol: pharmacology, metabolism, and misuse","volume":"124","author":"Miotto","year":"2017","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.vhri.2024.101013_bib6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2396","article-title":"Section on Anesthesiology and Pain Medicine, Committee on Drugs. Codeine: time to say \u201cno.\u201d","volume":"138","author":"Tobias","year":"2016","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.vhri.2024.101013_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012509","article-title":"Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews","volume":"10","author":"Els","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/s41598-017-02209-x","article-title":"Tolerability of opioid analgesia for chronic pain: a network meta-analysis","volume":"7","author":"Meng","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.vhri.2024.101013_bib9","first-page":"1374","article-title":"Factors influencing long-term opioid use among opioid naive patients: an examination of initial prescription characteristics and pain etiologies","volume":"18","author":"Shah","year":"2017","journal-title":"J\u00a0Pain"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bja.2018.03.009","article-title":"Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis","volume":"120","author":"Higgins","year":"2018","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jpainsymman.2018.09.005","article-title":"Pain and emergency department use in the last month of life among older adults with dementia","volume":"56","author":"Hunt","year":"2018","journal-title":"J\u00a0Pain Symptom Manag"},{"issue":"218","key":"10.1016\/j.vhri.2024.101013_bib12","first-page":"1","article-title":"The effectiveness and risks of long-term opioid treatment of chronic pain","author":"Chou","year":"2014","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"year":"2021","series-title":"Core Standards for Pain Management Services in the UK","key":"10.1016\/j.vhri.2024.101013_bib13"},{"issue":"2","key":"10.1016\/j.vhri.2024.101013_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3344\/kjp.2020.33.2.108","article-title":"All about pain pharmacology: what pain physicians should know","volume":"33","author":"Kim","year":"2020","journal-title":"Korean J Pain"},{"issue":"5","key":"10.1016\/j.vhri.2024.101013_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","article-title":"Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach","volume":"21","author":"Ramos-Go\u00f1i","year":"2018","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.vhri.2024.101013_bib16","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s11136-018-1929-x","article-title":"Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness","volume":"27","author":"Bilbao","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/21642850.2021.2022487","article-title":"Determinants of quality of life in individuals with chronic low back pain: a systematic review","volume":"10","author":"Agnus","year":"2022","journal-title":"Heal Psychol Behav Med"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gaceta.2013.04.006","article-title":"Systematic review of health-related utilities in Spain: the case of mental health","volume":"28","author":"Garc\u00eda-P\u00e9rez","year":"2014","journal-title":"Gac Sanit"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","article-title":"Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report","volume":"19","author":"Wolowacz","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067138","article-title":"Determinants of health-related quality of life (HRQoL) in the multiethnic Singapore population - a National cohort study","volume":"8","author":"Leow","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib22","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s12325-019-00932-7","article-title":"Outcomes associated with treatment of chronic pain with tapentadol compared with morphine and oxycodone: a UK primary care observational study","volume":"36","author":"Morgan","year":"2019","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.vhri.2024.101013_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jpainsymman.2017.07.025","article-title":"Opioid-induced constipation relief from fixed-ratio combination prolonged-release oxycodone\/naloxone compared with oxycodone and morphine for chronic nonmalignant pain: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Huang","year":"2017","journal-title":"J\u00a0Pain Symptom Manag"},{"issue":"3","key":"10.1016\/j.vhri.2024.101013_bib24","first-page":"E309","article-title":"Gastrointestinal adverse events in hospitalized patients following orthopedic surgery: tapentadol immediate release versus oxycodone immediate release","volume":"24","author":"Wang","year":"2021","journal-title":"Pain Phys"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1185\/03007995.2014.894501","article-title":"Clinical and economic evaluation of tapentadol extended release and oxycodone\/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain","volume":"30","author":"Coluzzi","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/03007995.2021.1993161","article-title":"Cost-effectiveness of tapentadol immediate release versus oxycodone immediate release for acute post-operative pain after major hip surgeries","volume":"38","author":"Wang","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.vhri.2024.101013_bib27","first-page":"724","article-title":"Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine","volume":"15","author":"Ikenberg","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.vhri.2024.101013_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health pathways to prevention workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib29","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s11096-021-01290-7","article-title":"Comparison of opioid prescribing upon hospital discharge in patients receiving tapentadol versus oxycodone following orthopaedic surgery","volume":"43","author":"Wang","year":"2021","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12871-017-0383-6","article-title":"Combatting pain after orthopedic\/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone\/naloxone","volume":"17","author":"Haeseler","year":"2017","journal-title":"BMC Anesthesiol"},{"issue":"8","key":"10.1016\/j.vhri.2024.101013_bib31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/pm\/pnx159","article-title":"Clinical use of pregabalin in general practice in Catalonia, Spain: a population-based cross-sectional study","volume":"19","author":"Vi\u00f1as-Bastart","year":"2018","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.vhri.2024.101013_bib32","doi-asserted-by":"crossref","first-page":"084","DOI":"10.26502\/aimr.0061","article-title":"Global Pain State Questionnaire: reliability, validity, and gender gap","volume":"4","author":"Barrachina","year":"2021","journal-title":"Arch Intern Med Res"},{"issue":"18","key":"10.1016\/j.vhri.2024.101013_bib33","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"9 suppl","key":"10.1016\/j.vhri.2024.101013_bib34","first-page":"256","article-title":"Differential diagnosis: nociceptive and neuropathic pain","volume":"12","author":"Nicholson","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.vhri.2024.101013_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2050-6511-14-39","article-title":"The association between prescription change frequency, chronic disease score and hospital admissions: a case control study","volume":"14","author":"Sino","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.vhri.2024.101013_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0212-6567(01)70406-4","article-title":"El EuroQol-5D: una alternativa sencilla para la medici\u00f3n de la calidad de vida relacionada con la salud en atenci\u00f3n primaria","volume":"28","author":"Herdman","year":"2001","journal-title":"Aten Prim"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0272989X0102100102","article-title":"A\u00a0comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states","volume":"21","author":"Badia","year":"2001","journal-title":"Med Decis Making"},{"issue":"5","key":"10.1016\/j.vhri.2024.101013_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0269216311406577","article-title":"Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review","volume":"25","author":"Mercadante","year":"2011","journal-title":"Palliat Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.101013_bib41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/pharmaceutics15041165","article-title":"The pharmacological treatment of chronic pain: from guidelines to daily clinical practice","volume":"15","author":"Marcian\u00f2","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-13085-5","article-title":"Oxycodone\/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study","volume":"12","author":"Barrachina","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.vhri.2024.101013_bib43","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s12325-018-0778-x","article-title":"Does \u2018strong analgesic\u2019 equal \u2018strong opioid\u2019? Tapentadol and the concept of \u2018\u03bc-load.\u2019","volume":"35","author":"Raffa","year":"2018","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","article-title":"Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","volume":"27","author":"Lange","year":"2010","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.vhri.2024.101013_bib45","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.vhri.2024.101013_bib46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.vhri.2024.101013_bib47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/2042098618760939","article-title":"Spontaneously reported adverse drug events related to tapentadol and oxycodone\/naloxone in Australia","volume":"9","author":"Abeyaratne","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"10.1016\/j.vhri.2024.101013_bib48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/papr.12515","article-title":"Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data","volume":"17","author":"Baron","year":"2017","journal-title":"Pain Pract"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12891-021-04012-2","article-title":"Quality of life and treatment satisfaction with pharmacological interventions in Chinese adults with chronic pain due to osteoarthritis","volume":"22","author":"Xue","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40359-019-0366-0","article-title":"Patients with chronic pain: evaluating depression and their quality of life in a single center study in Greece","volume":"7","author":"Rapti","year":"2019","journal-title":"BMC Psychol"},{"issue":"5","key":"10.1016\/j.vhri.2024.101013_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/papr.12361","article-title":"Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 trial","volume":"16","author":"Baron","year":"2016","journal-title":"Pain Pract"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2024.101013_bib52","first-page":"54","article-title":"Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone\/naloxone","volume":"156","author":"Kern","year":"2014","journal-title":"MMW Fortschr Med"},{"issue":"9","key":"10.1016\/j.vhri.2024.101013_bib53","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.vhri.2024.101013_bib54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/10245332.2018.1479997","article-title":"Predictive factors of daily opioid use and quality of life in adults with sickle cell disease","volume":"23","author":"Karafin","year":"2018","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12891-018-1991-0","article-title":"The influence of preoperative determinants on quality of life, functioning and pain after total knee and hip replacement: a pooled analysis of Dutch cohorts","volume":"19","author":"Hofstede","year":"2018","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2052-1847-5-2","article-title":"Determinants of pain, functional limitations and health-related quality of life six months after total knee arthroplasty: results from a prospective cohort study","volume":"5","author":"Desmeules","year":"2013","journal-title":"Sport Med Arthrosc Rehabil Ther Technol"},{"issue":"3","key":"10.1016\/j.vhri.2024.101013_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/ijerph17030743","article-title":"Sex-based differences in the quality of life of elderly Koreans with chronic musculoskeletal pain","volume":"17","author":"Jeong","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.vhri.2024.101013_bib58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41397-019-0118-9","article-title":"Gender based differences, pharmacogenetics and adverse events in chronic pain management","volume":"20","author":"Planelles","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"10.1016\/j.vhri.2024.101013_bib59","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s11136-018-1985-2","article-title":"Population health status based on the EQ-5D-Y-3L among adolescents in Sweden: results by sociodemographic factors and self-reported comorbidity","volume":"27","author":"\u00c5str\u00f6m","year":"2018","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.vhri.2024.101013_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035445","article-title":"Health-related quality of life and its determinants in patients with chronic low back pain at a tertiary hospital in Cameroon: a cross-sectional study","volume":"10","author":"Aminde","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.vhri.2024.101013_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychores.2019.02.010","article-title":"Somatic and psychosocial determinants of symptom severity and quality of life in male and female patients with chronic pelvic pain syndrome","volume":"120","author":"Piontek","year":"2019","journal-title":"J\u00a0Psychosom Res"},{"issue":"1","key":"10.1016\/j.vhri.2024.101013_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1017\/S1478951522001626","article-title":"Determinants of quality of life among Omani family caregivers of adult patients with cancer pain","volume":"22","author":"Muliira","year":"2024","journal-title":"Palliat Support Care"},{"issue":"6","key":"10.1016\/j.vhri.2024.101013_bib63","first-page":"505","article-title":"The determinants of the quality of life and pain of back pain patients","volume":"43","author":"Lee","year":"2010","journal-title":"J\u00a0Prev Med Public Heal"},{"issue":"23","key":"10.1016\/j.vhri.2024.101013_bib64","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1080\/09638288.2017.1355412","article-title":"Determinants of pain, disability, health-related quality of life and physical performance in patients with knee osteoarthritis awaiting total joint arthroplasty","volume":"40","author":"Lowry","year":"2018","journal-title":"Disabil Rehabil"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:34:41Z","timestamp":1762605281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":62,"alternative-id":["S2212109924000463"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101013","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life in Chronic Pain Treated With Tapentadol Versus Oxycodone\/Naloxone and Its Determinants: A Real-World, Single-Center Retrospective Cohort Study in Spain","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101013"}}